Solasia Pharma KK
TSE:4597

Watchlist Manager
Solasia Pharma KK Logo
Solasia Pharma KK
TSE:4597
Watchlist
Price: 30 JPY Market Closed
Market Cap: ¥7.8B

Operating Margin

-543.6%
Current
Declining
by 75.5%
vs 3-y average of -468%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-543.6%
=
Operating Income
¥-1.8B
/
Revenue
¥326m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-543.6%
=
Operating Income
¥-1.8B
/
Revenue
¥326m

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Solasia Pharma KK
TSE:4597
7.8B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-543.6%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Solasia Pharma KK
Glance View

Market Cap
7.8B JPY
Industry
Biotechnology

Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 77 full-time employees. The company went IPO on 2017-03-24. is a Japan-based pharmaceutical company. The firm is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. The company focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The firm's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).

Solasia Pharma KK Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-543.6%
=
Operating Income
¥-1.8B
/
Revenue
¥326m
What is Solasia Pharma KK's current Operating Margin?

The current Operating Margin for Solasia Pharma KK is -543.6%, which is below its 3-year median of -468%.

How has Operating Margin changed over time?

Over the last 3 years, Solasia Pharma KK’s Operating Margin has decreased from -303.6% to -543.6%. During this period, it reached a low of -1 308.4% on Sep 30, 2024 and a high of -107.9% on Sep 30, 2023.

Back to Top